Navigation Links
Pancreatic cancer patient survival 'significantly higher' with nab-paclitaxel, says TGen-led study
Date:10/19/2013

SCOTTSDALE, Ariz. Oct. 16, 2013 By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published today by The New England Journal of Medicine.

The study of 861 patients, conducted at 151 community and academic centers in 11 nations, found that the 431 patients assigned nab-paclitaxel in addition to the standard-of-care gemcitabine had significantly improved overall survival, progression-free survival, and drug response rates than for the 430 assigned to gemcitabine alone.

"This large, randomized, international, phase 3 study showed that the nab-paclitaxel plus gemcitabine led to a significant improvement in survival at all time points," said Dr. Daniel D. Von Hoff, TGen Distinguished Professor and Physician-In-Chief, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with TGen.

"The rate of survival was significantly higher in the nab-paclitaxel-gemcitabine group than in the gemcitabine group," said Dr. Von Hoff, lead author among the study's 23 co-authors and more than 130 researchers. He served as Principal Investigator of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), which included sites in North America, Europe and Australia.

Dr. Von Hoff, considered among the nation's leading authorities on pancreatic cancer, also was the principal investigator for the first clinical trial of gemcitabine, the first therapy to show improvement in survival for patients with pancreatic cancer. The FDA approved gemcitabine in 1996.

On Sept. 6, the U.S. Food and Drug Administration (FDA) approved nab-paclitaxel (produced by Celgene Corporation under the brand name Abraxane) for use in advanced pancreatic cancer patients. Abraxane previously was approved by the FDA for use in the treatment of metastatic breast cancer (2005) and advanced lung cancer (2012).

While it is still uncertain exactly how Abraxane works, Abraxane wraps traditional chemotherapy, paclitaxel, in near-nano sized shells of albumin, a protein that the tumor could recognize as food. Once inside the tumor, the Abraxane may act like a "Trojan Horse" to release chemotherapy and kill the cancer cells.

Participants treated with Abraxane plus gemcitabine lived, on average, 1.8 months longer than those treated with gemcitabine alone, and they experienced a delay in tumor growth (progression-free survival) that was, on average, 1.8 months later than the participants who only received gemcitabine.

Of note, 35 percent of patients who also received Abraxane survived more than 1 year, a 59 percent increase over the 22 percent of those receiving only gemcitabine who survived more than 1 year. Also, more than twice as many patients (9 percent) who also received Abraxane survived more than 2 years, compared to those (4 percent) who only received gemcitabine.

"This a major breakthrough, but there is more work to be done. Building on these results, we are evaluating new targeted agents in combination with the Abraxane/gemcitabine regimen," said Dr. Ramesh Ramanathan, Medical Director of the Virginia G. Cancer Center Clinical Trials at Scottsdale Healthcare, and MPACT principal investigator for the United States.

The most significant side effect from the addition of nab-paclitaxel was peripheral neuropathy, such as numbness in the hands and feet, although this occurred in only a small proportion of patients and was "rapidly reversible in most patients" by temporarily halting the drug and subsequently reducing its dosage. None of the patients experienced severe (grade 4) neuropathy.

The pancreas is a glandular organ behind the stomach that secretes enzymes to help digestion, and produces hormones, including insulin, which helps regulate blood-sugar metabolism.

"We are very grateful to the Seena Magowitz Foundation and to the Bedding Industry, which supported the research, leading to this important new survival-improving combination therapy," said Dr. Von Hoff. "We also appreciate the support of Stand Up To Cancer."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology technology :

1. New method yields insulin-producing pancreatic cell clusters
2. University of Colorado Cancer Center Study Shows that Bitter Melon Juice Prevents Pancreatic Cancer in Mouse Models
3. No rebirth for insulin secreting pancreatic beta cells
4. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
5. Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
6. Lisa Niemi Swayze And The Pancreatic Cancer Action Network Join More Than 160 Organizations In Asking Congress To Protect Medical Research Funding
7. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
8. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
9. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
10. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
11. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive ... 2014, FireflySci had the goal of bringing their powerful cuvette and spectrophotometer ... the path that FireflySci is going on as they add yet another mark on ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):